Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-05
DOI
10.3389/fimmu.2020.01128
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study
- (2020) Lingzhi Yan et al. BLOOD
- Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
- (2020) Carlos Fernandez de Larrea et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Engineering and Design of Chimeric Antigen Receptors
- (2019) Sonia Guedan et al. Molecular Therapy-Methods & Clinical Development
- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- (2019) Chuang Sun et al. Oncotarget
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Chimeric antigen receptor T cell persistence and memory cell formation
- (2019) Alexander D McLellan et al. IMMUNOLOGY AND CELL BIOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
- (2019) Cesar Sommer et al. MOLECULAR THERAPY
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of starting cellular material composition on chimeric antigen receptor T‐cell expansion and characteristics
- (2019) Nasha Elavia et al. TRANSFUSION
- Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
- (2019) Stefan Stoiber et al. Cells
- Gene editing for immune cell therapies
- (2019) Stefanie R. Bailey et al. NATURE BIOTECHNOLOGY
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
- (2019) Caitlin L. Costello et al. BLOOD
- Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Rakesh Popat et al. BLOOD
- Super-resolution microscopy reveals ultra-low expression of CD19 on myeloma cells that triggers elimination by CAR-T cells
- (2019) Thomas Nerreter et al. Clinical Lymphoma Myeloma & Leukemia
- Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
- (2019) Moo-Kon Song et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Chimeric antigen receptor T cell therapies for multiple myeloma
- (2019) Chao Wu et al. Journal of Hematology & Oncology
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- Recent updates on CAR T clinical trials for multiple myeloma
- (2019) Quande Lin et al. Molecular Cancer
- Determinants of response and resistance to CAR T cell therapy
- (2019) Stefanie Lesch et al. SEMINARS IN CANCER BIOLOGY
- The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells
- (2019) Hannah E. Hughes-Parry et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- CARs and other T cell therapies for MM: The clinical experience
- (2018) Sophia Danhof et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Current developments in immunotherapy in the treatment of multiple myeloma
- (2018) Martin Köhler et al. CANCER
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
- (2018) Christos Georgiadis et al. MOLECULAR THERAPY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
- (2018) Esther Drent et al. PLoS One
- Thymic involution and rising disease incidence with age
- (2018) Sam Palmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression
- (2018) Chungyong Han et al. Nature Communications
- Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
- (2018) De-Xiu Bu et al. Oncotarget
- Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
- (2018) Jean-Marc Hoffmann et al. Frontiers in Immunology
- The Pharmacology of T Cell Therapies
- (2018) Michael C. Milone et al. Molecular Therapy-Methods & Clinical Development
- CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment
- (2018) Hasan Mollanoori et al. HUMAN IMMUNOLOGY
- Tumors evading CARs—the chase is on
- (2018) Sarwish Rafiq et al. NATURE MEDICINE
- Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
- (2018) Alexander I. Salter et al. Science Signaling
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
- (2017) Silvia Arcangeli et al. MOLECULAR THERAPY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Steering CAR T cells to distinguish friend from foe
- (2017) Hillary Caruso et al. OncoImmunology
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview
- (2016) C. H. J. Lamers et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
- (2016) M. Sabatino et al. BLOOD
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
- (2016) M. Ruella et al. CLINICAL CANCER RESEARCH
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Multiple Myeloma: Diagnosis and Treatment
- (2016) S. Vincent Rajkumar et al. MAYO CLINIC PROCEEDINGS
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
- (2016) Nathan Singh et al. Science Translational Medicine
- Role of memory T cell subsets for adoptive immunotherapy
- (2016) Dirk H. Busch et al. SEMINARS IN IMMUNOLOGY
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
- (2015) H. G. Caruso et al. CANCER RESEARCH
- T cell receptor binding affinity governs the functional profile of cancer-specific CD8+T cells
- (2015) M. P. Tan et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Potential pitfalls of CRISPR/Cas9-mediated genome editing
- (2015) Rongxue Peng et al. FEBS Journal
- Multiple myeloma
- (2015) Atul Mehta Hematology
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
- (2015) Julien Valton et al. MOLECULAR THERAPY
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity
- (2015) De-Gang Song et al. Oncotarget
- A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
- (2014) B. Philip et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- The BAFF/APRIL system in SLE pathogenesis
- (2014) Fabien B. Vincent et al. Nature Reviews Rheumatology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
- (2013) E. Lanitis et al. Cancer Immunology Research
- Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
- (2012) YAWARA KAWANO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- Strength of TCR-Peptide/MHC Interactions and In Vivo T Cell Responses
- (2011) E. Corse et al. JOURNAL OF IMMUNOLOGY
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- CD138 shedding in plasma cell myeloma
- (2010) George Grigoriadis et al. BRITISH JOURNAL OF HAEMATOLOGY
- Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
- (2010) Marc Cartellieri et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
- (2009) M. Griffioen et al. HAEMATOLOGICA
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
- (2008) Gema Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started